HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines.

Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are potent antitumoral agents but their side effects limit their clinical use. A novel class of drugs, nitric oxide-donating NSAIDs (NO-NSAIDs), was found to be safer and more active than classical NSAIDs. This study explored the effect of the NO-donating sulindac derivative, NCX 1102, on three human urothelial epithelial carcinoma cell lines (T24, 647V, and 1207) and primary cultures of normal urothelial cells. Cytotoxicity, antiproliferative effect, cell cycle alterations, morphological changes, and apoptosis were investigated after treatment with NCX 1102 in comparison with the native molecule. After treatment, there was a cytotoxic effect (with IC(50) at 48 h of 23.1 micro M on 647V, 19.4 micro M on T24, and 14.5 micro M on 1207) and an antiproliferative effect on all three cell lines with NCX 1102 but not with sulindac. No effect was detected on normal urothelial cells. Flow cytometric analysis showed a differential NCX 1102-induced accumulation of cells in various phases of the cell cycle, depending on cell line and concentration. NCX 1102 induced an occurrence of multinucleated cells in all cell lines and mitotic arrest in 647V and 1207. NCX 1102-treated T24 and 647V cell lines showed a significant difference of apoptotic cell amount when compared to controls. Our results demonstrated a greater antiproliferative potency of NCX 1102 compared to its parent molecule sulindac, and suggested that this new NO-NSAID may have therapeutic impact in the management of bladder cancer.
AuthorsSandra Huguenin, Francis Vacherot, Laurence Kheuang, Jocelyne Fleury-Feith, Marie-Claude Jaurand, Manlio Bolla, Jean-Pierre Riffaud, Dominique K Chopin
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 3 Issue 3 Pg. 291-8 (Mar 2004) ISSN: 1535-7163 [Print] United States
PMID15026549 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antineoplastic Agents
  • nitrosulindac
  • Sulindac
  • Nitric Oxide
Topics
  • Anti-Inflammatory Agents, Non-Steroidal (pharmacology)
  • Antineoplastic Agents (pharmacology)
  • Apoptosis
  • Carcinoma (drug therapy, metabolism)
  • Cell Division
  • Cell Line, Tumor
  • Cell Nucleus (metabolism)
  • Dose-Response Relationship, Drug
  • Epithelium (pathology)
  • Flow Cytometry
  • Humans
  • Inhibitory Concentration 50
  • Nitric Oxide (metabolism)
  • Sulindac (analogs & derivatives, pharmacology)
  • Time Factors
  • Urinary Bladder Neoplasms (drug therapy, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: